The Cbfa1/Runx2 (referred to herein as Cbfa1) transcription factor has been shown to be essential for osteoblast differentiation and bone formation during embryogenesis. PTH given intermittently is a proven bone anabolic agent. Here, we investigated whether PTH regulates the expression and/or activity of Cbfa1 in osteoblastic cells and in a rat metatarsal organ culture assay. PTH was found to regulate Cbfa1 mRNA in the rat osteosarcoma cell line UMR106 in a concentration-dependent manner. The effect of PTH was mimicked by forskolin, an activator of adenylate cyclase leading to the protein kinase A pathway. PTH administered intermittently for 5 d in vivo was found to stimulate Cbfa1 protein in the rat proximal tibiae metaphysis. To demonstrate PTH regulation of Cbfa1 activity, a construct containing six tandem Cbfa1 binding elements fused to luciferase was shown to be rapidly stimulated in response to PTH. This stimulation preceded the effects on mRNA regulation and resulted from a protein kinase A-mediated increase in Cbfa1 activity. Finally, using a neonate rat metatarsal organ culture system, we demonstrated dose-dependent anabolic responsiveness to PTH and to Cbfa1 overexpression from an adenoviral construct. We further showed that Cbfa1 antisense oligonucleotides that blocked adenoviral Cbfa1-induced anabolic effects in this organ culture model also abolished the PTH-mediated anabolic increase. These findings suggest a requirement for Cbfa1 in mediating the anabolic effects of PTH.
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Thus, regulation of Cbfa1 expression or activity is an important mechanism by which PTH controls osteoblast function. (Molecular Endocrinology 17: 423-435, 2003)
P TH IS A POTENT modulator of bone metabolism (1) . In experimental animals and patients with osteoporosis, intermittent administration of PTH increases bone mass by stimulating de novo bone formation (2) (3) (4) (5) (6) (7) . At a cellular level, this increase in bone mass is associated with an increased activity of existing osteoblasts and an increased differentiation of osteoblast precursors or recruitment of lining cells to active osteoblasts (8, 9) . The molecular mechanisms that mediate these osteoblastic effects of PTH remain to be elucidated. Marker genes that typically signal the bone formation process (such as extracellular matrix proteins, osteocalcin, osteopontin, collagen type 1, and alkaline phosphatase) have been well studied (9) (10) (11) (12) . Presently, a number of other genes have been shown to be regulated by PTH in vivo or in vitro (13) (14) (15) (16) (17) (18) (19) . Although these genes have been associated with PTH actions, there are limited data demonstrating their requirement in bone formation or in PTH anabolic action. We propose that the PTH-induced anabolic effect on bone is likely to involve the control of a master regulatory gene(s) whose expression and activity governs osteoblast function.
The recent discovery of Cbfa1 (Runx2, OSF2, AML3, PEBP2␣a) as a master regulatory gene in the osteoblast is of great interest. Cbfa1 is a member of the runt family of transcription factors (20) whose expression is absolutely required for the differentiation of osteoblastic precursors and in modulating the activity of mature osteoblasts (21) (22) (23) (24) . Targeted deletion of the Cbfa1 gene resulted in a complete lack of skeleton and absence of functional osteoblasts due to maturational arrest (25, 26) . Specific expression of a dominantnegative Cbfa1 in mature osteoblasts resulted in severe reduction in bone formation and bone mass due to a decrease in osteoblast activity (27) . Overexpression of Cbfa1 by the type I collagen promoter in a transgenic mouse produced defective osteoblasts that had clear effects on the skeleton, demonstrating the need for proper regulation of this gene in maintaining bone homeostasis (28, 29) . Additionally, several in vitro experiments have demonstrated that Cbfa1 is a major regulator of the osteoblast phenotype and is necessary for osteoblast-specific expression of genes such as osteocalcin, collagen type 1, osteopontin, and bone sialoprotein (24, 25, 27) .
Based on in vitro data and the phenotypes of mice with altered Cbfa1 expression, it seems likely that the expression and regulation of Cbfa1 activity in osteoblastic lineage cells might be important in determining bone formation induced by anabolic agents. At the present time, there are limited data on the expression and regulation of Cbfa1 by PTH. In this work, we evaluated the role of Cbfa1 in PTH action. We show that PTH regulates expression of Cbfa1 in a time-and dose-dependent manner. We found that regulation occurred both at the Cbfa1 mRNA level, and at the posttranslational level to increase the activity of Cbfa1 protein. The dose-dependent activity on mRNA and protein expression suggests an anabolic function for PTH at lower doses. However, higher doses of PTH decreased Cbfa1 mRNA and protein levels. Using the rat neonate metatarsal organ culture model (MT model) (30) , PTH-mediated increases in endochondral ossification were also found to be dose dependent. Finally, a Cbfa1-specific antisense oligonucleotide (ASO) that blocks adenoviral Cbfa1-induced bone anabolic activity in this model, completely reversed the PTH anabolic effect. Collectively, this study points to a critical role for Cbfa1 in mediating the bone anabolic effects of PTH.
RESULTS

PTH Regulation of Cbfa1 Expression in Rat UMR106 Cells
We initially examined the ability of PTH to regulate Cbfa1 mRNA levels in the rat osteoblast cell line UMR106, which is known to express PTH receptors and is capable of responding to PTH by stimulating intracellular cAMP levels (31) . Treatment of UMR106 cells with the fully active PTH (1-38) revealed a concentration-dependent and time-dependent regulatory profile (Fig. 1) . The dose-dependent regulation, 24 h after PTH treatment showed that low levels of PTH (0.05-5.0 nM) stimulated Cbfa1 mRNA up to 4-fold, whereas higher levels of PTH (50 nM) had little effect or decreased expression of Cbfa1 mRNA (Fig. 1A) . A time course study using 5 nM PTH demonstrated maximal stimulation of Cbfa1 mRNA at 24 h, whereas a high dose of PTH (1000 nM) resulted in a decrease of Cbfa1 mRNA at 12 h (Fig. 1B) . These effects were predominantly mediated by the protein kinase A (PKA) signaling pathway, as the adenylate cyclase activator forskolin, showed a stimulatory effect on Cbfa1 mRNA after 24 h at 100 nM but showed inhibition of Cbfa1 mRNA at the higher 10 M dose (Fig. 1C) . Western blot analysis of Cbfa1 protein from UMR106 nuclear extracts of cells treated with different concentrations of PTH, for 24 h, confirmed the biphasic regulation seen at the RNA level (Fig. 2) . Thus, the effects on Cbfa1 mRNA and protein expression in response to PTH are dose dependent and include both up-regulation and down-regulation of Cbfa1 depending on the concentration of PTH used.
In Vivo Stimulation of Cbfa1 Protein by PTH
To determine if the regulation of Cbfa1 by PTH could occur in vivo, we dosed Sprague Dawley rats with 80 g/kg PTH 1-38 for 5 d. Transverse sections of proximal tibiae obtained from these rats 1 h after d 5 of injection show increased intensity of Cbfa1 nuclear staining using a Cbfa1-specific antibody compared with vehicle control (Fig. 3) . This increased nuclear staining suggests increased Cbfa1 expression in vivo after an anabolic PTH treatment schedule.
PTH Regulation of Cbfa1 Activity in Rat UMR106 Cells
We next wanted to determine if the activity of Cbfa1 was modified in response to PTH treatment. We used a reporter construct consisting of 6 tandem Cbfa1 binding elements (6XOSE) cloned in front of an osteocalcin minimal promoter and fused to the luciferase (Luc) reporter gene (Fig. 4A) . This construct, which is highly responsive to Cbfa1 protein (23) , was transfected into UMR106 cells, and stable transfectants were isolated. Based on the stimulation of Cbfa1 mRNA seen at 24 h, we initially treated with PTH or 8-bromo-cAMP for 24 h. As shown in Fig. 4B , the 6XOSE Luc reporter was stimulated in a dose-responsive manner. An initial time course study revealed that PTH stimulation of the Cbfa1 response element was faster than 24 h, resulting in a large increase in Luc activity at 4 h and gradually decreasing over time to approximately 2-fold at 48 h. In fact, PTH induced stimulation as early as 1 h after treatment with a maximal activation seen at 4 h (Fig. 4C) . To show that the stimulation of the 6XOSE construct by PTH was not specific to a particular UMR106 clone, we also examined transient transfectants of UMR106 with the 6XOSE/Luc construct as well as with a mutant 6XOSE/Luc construct, which was previously shown to poorly respond to Cbfa1 (23) . As shown in Fig. 5A , after 4 h of PTH treatment, Luc activity was increased approximately 10-fold when the wild-type 6XOSE construct was transfected into the cells, whereas the mutant 6XOSE was only marginally increased. Moreover, a stable 6XOSE/Luc clone of the ROS17/2.8 cell line responded nearly identically to the UMR106 clone used for the majority of these experiments (data not shown). Evidence that stimulation of the PKA/cAMP pathway appeared to be responsible for Cbfa1 protein activation was shown by the ability of 8-bromo-cAMP to stimulate the Cbfa1 response element (Figs. 4B and 5B) in a doseresponsive manner similar to PTH (Fig. 5C ). Additional evidence of the PKA pathway involvement was seen with the use of PTH analogs, which either signal both the PKA and protein kinase C (PKC) pathways (PTH 1-38), or just either the PKA (PTH 1-31) or PKC (PTH 3-34) pathways (32, 33) (Fig. 5D) . The PKA inhibitor, H89 (34) , was also used to show that the 6XOSE stimulation by PTH was almost entirely mediated through a PKA-dependent mechanism (Fig. 5E) . Interestingly, whereas 10 nM of PTH was sufficient to maximally stimulate Cbfa1 activity (Fig. 5 , A and C), higher concentrations did not appreciably reduce this stimulation, which contrasts with what was observed for Cbfa1 mRNA and protein expression (Figs. 1A and 2 ).
Bone Anabolic Activity of PTH in a Rat Metatarsal Organ Culture Model
To assess a functional role of Cbfa1 in PTH signaling in a more biologically relevant setting, we employed A, UMR106 cells were treated for 24 h with the concentrations (nM) of PTH 1-38 indicated. The top band resulted from hybridization with a rat Cbfa1 probe, whereas a rat GAPDH cDNA probe (bottom band) was used as a control for amount of mRNA loaded. The graphic representation of the amount of Cbfa1 mRNA was derived from PhosphorImager quantitation to calculate relative intensity of the Cbfa1 bands normalized to GAPDH. This represents one of four different experiments in which an approximate 4-fold stimulation of Cbfa1 mRNA was seen at the 0.5-5.0 nM concentration range. B, UMR106 cells were treated for up to 48 h with either 5 nM (black bar) or 1 M (gray bar) PTH 1-38 before RNA was extracted and analyzed by Northern blot. The relative expression was derived from PhosphorImager quantitation of the Cbfa1 bands and GAPDH bands from each mRNA source. C, UMR106 cells were treated with the PKA activator, forskolin for 24 h, and the RNA blot was hybridized to Cbfa1 and GAPDH probes as described above. Note the increase in Cbfa1 mRNA with 100 nM forskolin and decrease with 10 M.
an organ culture model that is capable of responding to bone anabolic agents (35) . This model allows for the appropriate interplay between various cell types in their natural matrix microenvironment. In this model, neonatal rat metatarsal bones are removed and individually cultured in a 96-well plate (30) . The length of the central, mineralized bone in the putative diaphyseal region of the metatarsal is quantitatively imaged at the beginning of the 7-d culture period, and then again at the end of the 7-d incubation period to measure relative growth with treatment compared with vehicle control (see inset to Fig. 6A ). Increase in mineralized bone over the 7 d of incubation is defined as bone anabolic activity in this model. We found that PTH at a concentration of 1 and 10 nM had a reproducible and significant stimulatory effect on these bones with about a 3-fold increase in growth compared with vehicle control (Fig. 6A ). At higher PTH concentrations, the stimulatory effect was reduced, and at levels of 100 nM and greater, there was no significant stimulation of the metatarsals. This low dose-dependent induc-
Fig. 2. PTH Regulates Cbfa1 Protein Levels
UMR106 cells were treated with various concentrations (shown in nM) of PTH for 24 h. Nuclear extracts were isolated and nuclear proteins analyzed by Western blot analysis using antibody specific for the N-terminal 26 amino acids of the osteoblastspecific form of Cbfa1. The blot was reanalyzed with antibody to actin to measure equivalency of extracts loaded onto the gel. Specificity of the Cbfa1 antibody is shown by the near-total disappearance of the correct size Cbfa1 band when the antibody is preincubated with the immunizing Cbfa1 peptide before Western analysis (inset). tion of bone formation activity is consistent with the PTH doses used to increase Cbfa1 mRNA in UMR106 cells.
Various concentrations of PTH 3-34, PTH 1-38, and a PKA-specific inhibitor H-89 (34) were used to study the role of PKA vs. PKC pathways in mediating these anabolic changes in the rat neonate metatarsal model. Statistically significant (P Ͻ 0.05) activity compared with vehicle control was observed at 1 nM PTH 1-38, and this activity was significantly reduced by cotreatment with 50 nM H-89 (Fig. 6B) . In contrast, PTH 3-34 failed to show significant anabolic activity at 10 nM and 100 nM concentrations (Fig. 6B) . The 10-fold higher dose of PTH (3-34) used was based on its relative affinity to the PTH receptor type I (36). Interestingly, H-89 cotreatment did not completely reverse the PTH-induced bone anabolic activity as it did in the 6XOSE reporter assay (refer to Fig. 5C ). To more fully understand the role of PKA (vs. PKC) in mediating this activity, we used a form of PTH, previously described by Takasu et al. (36, 37) . This form of PTH (Gly 1, Arg 19) is devoid of any PKC activity and binds the PTH receptor type I with similar affinity as the PTH 1-38. PTH (Gly 1, Arg 19) induces a dose-dependent bone anabolic activity in the MT model which is similar to that of PTH 1-38 (refer to Fig. 6C ). Collectively, these results using PKA-specific forms of PTH and PKA-specific inhibitors indicate that the dose- dependent bone anabolic activity of PTH is largely driven by its PKA specific signaling component.
Bone Anabolic Activity of Cbfa1 in the Rat Metatarsal Organ Culture Model
To investigate the consequences of Cbfa1 overexpression in this model, we infected the metatarsals with an adenoviral construct that expresses Cbfa1 protein. We tested the activity of this adenoviral Cbfa1 construct and found that it markedly stimulated the 6XOSE/Luc construct (but not the mutated 6XOSE/Luc) transfected into U2OS or C2C12 cells, both of which express reduced amounts of endogenous Cbfa1 protein compared with UMR106 (data not shown). A dose-responsive stimulation of metatarsal bone growth was found after Cbfa1 adenovirus was applied each day for 7 d (Fig. 7A) . A control adenoviral construct expressing only ␤-galactosidase (␤-gal) had no significant effect on metatarsal bone growth. Western blot analysis of protein lysates from several pooled infected metatarsals using an antibody to Cbfa1 revealed the full-length Cbfa1 protein expressed from the adenoviral construct (Fig. 7B) . The parallel infection of metatarsals with the control adenovirus was unable to produce a detectable Cbfa1 band.
The adenoviral construct was engineered with a green fluorescent protein (GFP) tag downstream from the Cbfa1 gene using an internal ribosomal entry site to generate a bi-cistronic message. This allowed visualization of the infected regions within these treated metatarsals by following GFP fluorescence over time. In the metatarsals infected with the Cbfa1 adenoviral construct, we found a dose-dependent GFP signal (as early as 3 d) in the periosteum as well as in the putative diaphyseal region of the metatarsal (Fig. 7D) .
To further assess the effects of Cbfa1 on metatarsal bone growth, ASO specifically targeted against rat Cbfa1 (22) , were used to treat metatarsals along with an optimal dose (1 l/ml) of Cbfa1 adenovirus. The Cbfa1 ASO blocked metatarsal stimulation by the Cbfa1 adenovirus, but a control oligonucleotide of scrambled Cbfa1 sequence (Scr) had no effect on this stimulation (Fig. 7A) . In addition, the ASO or Scr oligos did not affect the growth of the ␤-gal adenovirus treated metatarsals.
PTH Bone Anabolic Activity in the Rat Metatarsal Organ Culture Model Is Cbfa1 Dependent
We have previously shown that in addition to PTH, another anabolic agent, bone morphogenetic protein (BMP)-4, increased metatarsal bone length and depended on Cbfa1 expression for activity (30) . To test the role of Cbfa1 in mediating PTH-induced bone anabolic activity in the metatarsal model, we pretreated ASO to Cbfa1 along with 10 nM PTH. Cbfa1 ASO (but not Cbfa1 Scr) completely blocked the PTH stimulation of metatarsal growth, suggesting a Cbfa1-dependent mechanism (Fig. 8) . These results thus implicate a functional requirement for Cbfa1 expression in the bone anabolic activity induced by PTH.
DISCUSSION
We have demonstrated that PTH, through activation of the PKA pathway, regulates the expression and activity of Cbfa1, and this effect is required for PTHinduced bone anabolic activity in a metatarsal bone organ culture. PTH was able to maximally increase 6XOSE/Luc activity from endogenous Cbfa1 protein in 4 h. It is likely that these early effects of PTH are mediated through stimulation of PKA to posttranslationally activate Cbfa1. Earlier reports have implicated specific signaling pathways, such as MAPK and PKA in modulating the activation function of Cbfa1 protein (38, 39) .
The increase in Cbfa1 transcriptional activity as measured by the 6XOSE appears to be maximal after 4 h of PTH stimulation. A similar PTH-induced early increase (ϳ4 h) has been reported for the osteocalcin promoter (40) , a gene that is directly regulated by Cbfa1 (24) . However, there is a delayed effect (24 h) on the regulation of Cbfa1 mRNA, which is very dependent on the concentration of PTH. Thus, whereas lower concentrations of PTH (5 ϫ 10 Ϫ11 to 5 ϫ 10 Ϫ9 M) stimulate expression of Cbfa1 mRNA and protein, higher concentrations of PTH tend to decrease their levels. It is noteworthy that in the metatarsal study PTH anabolic activity is only seen at the lower concentrations of PTH and suggests that the functional consequences of PTH-regulated Cbfa1 expression are important. It is likely that a combination of effects on Cbfa1 expression and on Cbfa1 activation are at play in determining the eventual anabolic or catabolic response to a given PTH dosing regimen in vivo. Results from the PTH1-28 (Gly 1, Arg 19) -treated metatarsals clearly indicate that the effects of PTH are largely dependent on the PKA pathway stimulated by cAMP accumulation via the G s protein-coupled PTH receptor.
Previous work by others has shown a connection between PTH and activation of Cbfa1 in the regulation of the MMP-13 promoter (41) (42) (43) . These researchers showed that a cooperative interaction of Cbfa1 and activator protein (AP)-1 at adjacent binding sites on the promoter is necessary for promoter induction by PTH. PTH was found to increase DNA binding activity of AP-1, whereas no increase in binding of Cbfa1 was apparent. The regulation of MMP-13 transcription by PTH required Cbfa1 but did not involve the direct activation of Cbfa1, only the increased DNA binding activity of AP-1. Recently, however, it was reported that stimulation of the MMP-13 promoter by PTH was blocked by PKA inhibitors but not other pathway inhibitors (39) . That study demonstrated that a Gal4 DNA binding domain fused to the AD3 activation domain of Cbfa1, containing a consensus PKA site (see Ref. 44) , was phosphorylated and transcriptionally activated by PTH. Thus, in addition to an increase in AP-1 binding, it was proposed that PTH induced a PKA-dependent transactivation of Cbfa1. It remains to be proven that PKA-dependent phosphorylation is responsible for native Cbfa1 activation, but our results would be consistent with that mechanism. Accordingly, our results demonstrate PKA-mediated increases in endogenous Cbfa1 activity as measured by the 6XOSE reporter. Tintut et al. (45) have demonstrated that in the MC3T3 osteoblastic cell line, continuous activation of the cAMP pathway over a period of days can stimulate the degradation of Cbfa1 through activation of the 26S proteasome complex. They noted, however, that reductions of Cbfa1 were not observed before 32 h of treatment, and in fact, greater amounts of Cbfa1 protein were observed with forskolin treatment after 24 h. In our studies, we found that only lower concentrations of PTH or PKA activators increased Cbfa1 message and protein, whereas higher concentrations did not (Fig. 1) . It has been reported that continuous administration of PTH at high doses results in a longer period of PTH exposure with a net catabolic effect on bone, whereas intermittent or low PTH concentrations result in an anabolic response (2) (3) (4) . Under these catabolic conditions, a recent study showed that Cbfa1 mRNA is down-regulated by PTH (46) . Hence, it would be interesting to study the relationship between the dosedependent effect of PTH on Cbfa1 mRNA and the anabolic or catabolic effect on bone.
Other studies have suggested stimulation of Cbfa1 activity by MAPK pathways. Xiao et al. (38) demonstrated phosphorylation of Cbfa1 in MC3T3 cells by MAPK kinase (MEK1). In that study, constitutively active MEK1 was able to stimulate osteocalcin mRNA and an osteocalcin promoter/reporter construct through the osteoblast-specific element (OSE) response element found in the osteocalcin promoter. This pathway linked earlier work addressing integrin activation by extracellular matrix, to stimulation of bone markers through Cbfa1 activation (47) . Other reports have shown that the bone morphogenetic proteins BMP-2, -4, or -7 are capable of stimulating Cbfa1 expression (24, 48, 49) . Whereas new Cbfa1 expression in response to BMP may be responsible for the osteogenic activity of BMP, the kinetics of Cbfa1 induction after BMP treatment suggests that it is more likely the result of an osteogenic processes already underway. The SMAD proteins, which act as transcriptional mediators of BMP and other TGF-␤ family members, have been shown to interact with Cbfa1 (50, 51) . This interaction may provide a potential pathway by which BMP can effectively increase the activity of Cbfa1, although it has recently been shown that the osteogenic actions of Cbfa1 do not absolutely require association with SMAD1/SMAD5 (52). Conversely, it should be noted that our previous work (30) suggests a requirement for Cbfa1 in the ability of BMP-4 to increase metatarsal bone growth.
In conclusion, our findings point to a mechanism involving Cbfa1 by which PTH may regulate osteoblast function. These findings suggest that Cbfa1 is a central target that mediates the anabolic effects of PTH on bone. In vitro, the immediate response to PTH appears to be a PKA-dependent modulation resulting in enhanced transactivation of Cbfa1-mediated transcription. Subsequent to this PKA-mediated transactivation effect, PTH regulates Cbfa1 expression in a concentration-dependent manner. This concentration-dependent effect on Cbfa1 expression correlates with the dose-dependent bone anabolic effect as measured by the metatarsal organ culture model. Finally, using specific ASOs targeted against Cbfa1, we show that the PTH-induced anabolic activity is completely reversed in this ex-vivo bone model. It remains to be determined how central Cbfa1 is to other pathways of anabolic bone formation.
MATERIALS AND METHODS
Cell Culture
UMR106 cells were maintained in DMEM/F12 (3:1) media supplemented with 10% fetal bovine serum (FBS), 2 mM L-
Fig. 8. Cbfa1 Expression Is Necessary for PTH Stimulation of Metatarsal Bone Growth
Metatarsals were treated with 10 nM PTH 1-38 alone, or pretreated with 10 M rat Cbfa1 ASO or control oligos (Scr). Both oligos alone were found to have no significant effect on metatarsal growth. Statistically significant difference (P Ͻ 0.05) from control ‫)ء(‬ or from PTH treatment (ࡗ).
glutamine, and 1ϫ antibiotic-antimycotic (Invitrogen Corp., Carlsbad, CA). The cells were incubated in reduced serum (0.5% FBS) overnight before PTH treatment for the RNA and protein studies in UMR106. Stable cell lines containing six tandem OSE repeats in front of an osteocalcin minimal promoter fused to Luc (23) were generated in UMR106 cells using Fugene 6 Transfection Reagent (Roche Molecular Biochemicals, Indianapolis, IN). The pSV2Neo plasmid was cotransfected for geneticin selection. Clones were maintained in parental culture media containing 500 g/ml geneticin. All cultures were maintained in a humidified 5% CO 2 atmosphere at 37 C.
RNA Isolation and Northern Analysis of UMR106 Cells
Total RNA from UMR106 cells was isolated by a guanidium extraction and CsCl gradient centrifugation procedure as described in Ref. 53 . RNA (25 g) was loaded onto formaldehyde/agarose (10%/1.2%) gels. After electrophoretic separation, RNA was transferred to Nytran filters (Schleicher & Schuell, Inc., Keene, NH) and hybridized to random primerlabeled cDNA probes using modified Church hybridization conditions (53) . Bands were visualized and quantitated by PhosphorImager and ImageQuant software (Molecular Dynamics, Inc., Amersham Biosciences, Sunnyvale, CA). Probes used were rat Cbfa1 (cloned as a PCR product from the DNA binding RUNT domain) and rat glyceraldehyde phosphate dehydrogenase (GAPDH; Ref. 14).
Transient Transfections and Luc Assays
A total of 1.7 ϫ 10 6 UMR106 cells per 100-mm dish were plated approximately 24 h before being transiently transfected with 15 g of either the wild-type 6XOSE (above) or a mutant 6XOSE driving Luc (23) using Lipofectamine Plus Reagent (Invitrogen Corp.). Cells were incubated for 3 h in serum-free media, then overnight in 2% FBS media. Cells were then dispersed evenly to a 96-well culture plate in 2% FBS complete media and allowed to adhere overnight. UMR106 stable clones were seeded at 3 ϫ 10 Ϫ4 cells per well in 96-well plates in 10% FBS complete media. Once adhered, cells were serum starved in 0.5% FBS media overnight. Both transiently transfected and stable clones were treated with human PTH (1-38) (Zeneca Pharmaceuticals, Wilmington, DE) for 4 or 24 h in 0.5% FBS complete media at given concentrations. PKA inhibitor H89 was purchased from Calbiochem (La Jolla, CA). Cells were harvested directly in the wells with 30 l lysis buffer (Tropix, Inc., Bedford, MA) containing 0.5 mM dithiothreitol. Luc activity was determined by injecting 100 l Luc reagent (Promega Corp., Madison, WI) per well. Relative light units were detected on a Luminoskan RT (Thermo Labsystems, Franklin, MA) luminometer with a 5-sec read time.
Western Blot Analysis
Nuclear extracts were isolated from treated cells (reduced serum to 0.5% overnight) as described (54) and the protein quantitated using Bio-Rad Laboratories, Inc. (Hercules, CA) protein dye reagent. Acrylamide gels (10% Tris/glycine, Invitrogen Corp.) were run with 20 g of protein from each sample and electroblotted to nitrocellulose (Invitrogen Corp.). See-Blue protein markers (Invitrogen Corp.) were used to estimate the molecular weight of protein bands. Blots were blocked for at least 45 min in Blotto (TBST, 10 mM Tris-HCl at pH 8.0, 150 mM NaCl, 0.05% Tween-20 plus 5% nonfat dry milk) before incubation with 1:2500 dilution of anti-Cbfa1 specific antibody. The Cbfa1-specific antibody was generated in rabbits (Genosys Biotechnologies, Inc., The Woodlands, TX) with a peptide corresponding to the N-terminal 26 amino acids of Cbfa1: MASNSLFSAVTPCQQSFFWDP-STSRR. To show specificity of antibody for Cbfa1, 5 g of this peptide were preincubated for 30 min at 30 C with the antibody before hybridization with a nitrocellulose blot of UMR106 protein extract. Serum antibody was IgG purified using the Bio-Rad Laboratories, Inc. (Hercules, CA) EconoPac serum IgG DEAE columns, as per manufacturer's instructions. A horseradish peroxidase (HRP)-conjugated antirabbit IgG polyclonal (Amersham Pharmacia Biotech, Piscataway, NJ) secondary antibody was used at 1:2000 dilution. Amersham Pharmacia Biotech enhanced chemiluminescence Western blotting reagents were used for signal detection. An actin antibody (SC1616, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was used at 1:200 dilution, and HRP-conjugated antigoat secondary antibody used at 1:75,000 dilution to show equivalent loading on the Western blot.
Immunohistochemistry Analysis of Cbfa1 Protein in Rat Femur
Four-week-old female Sprague-Dawley rats (Harlan, Indianapolis, IN) were maintained on a 12-h light, 12-h dark cycle at 22 C with ad libitum access to food of 1.2% Ca, 0.9% P in content (TD5001, Teklad, Madison, WI). Rats were sc injected daily with vehicle (20 mM NaH 2 PO 4 , 0.9% NaCl, and 2.13 g/liter mannitol), or PTH (1-38) 80 g/kg⅐d for 5 d. Animals were killed at 1 h after the last dose.
Immunohistochemical staining was conducted on 5-m thick, decalcified proximal tibial sections with a polyclonal antibody to Cbfa1 (see Western Blot Analysis section above) using an indirect immunoenzymatic Streptavidin detection method (Vector Laboratories, Inc., Burlingame, CA). Briefly, tissue sections were deparaffinized and rehydrated through a series of graded alcohols to distilled water. Sections were washed three times in PBS containing Brij 35 (0.1%). A PBS buffer wash was included after application of each histological reagent unless otherwise noted. An avidin/biotin blocking kit (Vector Laboratories, Inc.) was applied to block nonspecific binding, followed by preincubation in 10% normal goat serum for 30 min at room temperature. The Cbfa1 antibody at 1:300 was applied for 60 min at room temperature in a humidified chamber. The secondary antibody was applied for 30 min and endogenous peroxidase activity was blocked with 3% hydrogen peroxide in PBS for 30 min. A PBS buffer wash was performed and a Streptavidin HRP-conjugated labeling complex was applied for 30 min. Cbfa1 expression was visualized with a diaminobenzidine chromogen substrate (Sigma-Aldrich Corp., St. Louis, MO). Sections were counterstained in Mayer's Hematoxylin (Sigma-Aldrich Corp.), dehydrated, and mounted for subsequent light microscope evaluation.
Rat Neonate Metatarsal Culture
Newborn Sprague Dawley rats (Harlan, Indianapolis, IN) were killed at d 0 and the metatarsals were surgically isolated and placed in BGJ6 media (Life Technologies, Inc., Rockville, MD) without serum containing 10% antibiotic/antimycotic solution (Life Technologies, Inc.). Metatarsals were cultured for 7 d in a 96-well round bottom Petri dish (Nunclon, Nunc Products, Roskilde, Denmark) under 5% CO 2 at 37 C (see Ref. 30) . Fresh media containing treatments or vehicle were replaced every 24 h. The metatarsals were imaged under a light microscope at the start of the 7-d incubation and changes in endochondral ossification were quantified at the end of the 7-d incubation period using an Image Pro analysis software. Data are shown as a percent change from d 0-7, performed in quadruplicate.
For treatment, wells were replaced with fresh media containing PTH vehicle (150 mM NaCl, 1 mM HCl, 0.1% BSA), and PTH analogs at the doses indicated. PTH analog (Gly 1, Arg 19) was purchased from AnaSpec, Inc. (San Jose, CA). Fresh media containing the appropriate amounts of PTH analogs were provided every 24 h for 7 d. Adenoviral-Cbfa1 and adenoviral-␤-gal (control) treatment was done daily with the indicated volumes of adenovirus stocks. For antisense oligomer assays, metatarsals were pretreated for 1 h with 10 M rat Cbfa1/Runx2 antisense oligonucleotides (ASO) that have been described previously (22) . As a control, scrambled sequence oligonucleotides (Scr) of the ASO were used at the same concentration. For protein analysis, a set of 12 individual MT cultures treated with 1 l/ml of Adeno-␤-gal or Adeno-Cbfa1 for 7 d were boiled in a 6ϫ SDS-PAGE loading dye and run on a 1.2% Tris-Glycine gel and transferred to a nitrocellulose membrane. Western blot analysis was performed as described earlier using antibodies raised against the N terminus of Cbfa1.
Adenoviral Cbfa1
Human Cbfa1 cDNA (amino acids 1-528 with a BglII linker) was cloned into the BglII site of the pQBI-AdCMV5-IRES-GFP vector (Quantum Biotechnologies, Montré al, Canada). Recombinant adenovirus was generated and amplified in QBI-293A cells using the Adeno-Quest kit and methods (Quantum). GFP positive viral plaques were screened for Cbfa1 expression by Western analysis. The control ␤-gal adenovirus used was the QBI-Infectϩ virus with a lacZ gene expressed from the cytomegalovirus promoter (Quantum). U2OS, C2C12, and C3HT101/2 cells transfected with 6XOSE/Luc were infected with recombinant adenovirus to verify functional Cbfa1 expression. Amplified viral preparations were purified using the Viraprep filtration system (Virapur, Carlsbad, CA).
